Abstract 1160P
Background
Nivolumab obtained marketing authorization in advanced melanoma (AM) with weight-adjusted (WA) dose administration (3 mg/kg/2 weeks) 1. Based on modeling studies (no clinical data), EMA advised in 2018 that nivolumab should be administered in flat dose regimen (240 mg/2 weeks or 480 mg/4 weeks) 2 3. The aim of the FLATIMEL study was to compare clinical outcomes of AM patients treated with both nivolumab dose calculation methods.
Methods
AM patients were prospectively included in the national multicenter MelBase database since 2013 (NCT02828202). Patients treated by nivolumab monotherapy in first line enrolled in MelBase were included in our study. We compared safety and efficacy of nivolumab in 2 groups of patients treated by flat or WA dose. The primary endpoint was the incidence of immune-related adverse events (irAEs) of grade ≥ 3. Secondary endpoints were incidence of irAEs of any grade, overall survival (OS) and progression free survival (PFS). Inverse probability of treatment weighting was used to balance groups on their baseline characteristics.
Results
Between June 2015 and January 2022, 546 patients followed in MelBase were included in this study: 252 in the flat dose group and 294 in the WA group. Patients with metastatic organs ≥ 3 (p<0.0001), brain metastasis (p=0.0005) or M1c AJCC (7th edition) tumor stage (p=0.001) were more frequent in the WA group. After weighting, no difference between both groups was observed for irAEs grade ≥ 3 (n=65, 12%), (p= 0.51), whereas irAEs of any grade (n=314, 57.5%) were more frequent in the flat dose group (p=0.044), especially muco-cutaneous and endocrine toxicities. Median OS was 32.3 and 20.6 months in flat dose and WA group respectively (p= 0.004), and median PFS was 3.5 and 2.8 months, respectively (p= 0.003).
Conclusions
There was no difference in the incidence of severe irAEs between AM patients treated by WA or flat dose of Nivolumab. Survival results were superior in the flat dose group, which may be explained by a temporal bias. Cost effectiveness studies are necessary.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
MELBASE database.
Funding
INCa, Roche, BMS, Novartis, MSD, Amgen.
Disclosure
L. Mortier: Financial Interests, Personal, Advisory Board: BMS, MSD, Pierre Fabre, Novartis, Sanofi. H. Montaudie: Financial Interests, Personal, Research Funding: BMS, Merck, MSD, Novartis, Pierre Fabre, Leo pharma, Checkpoint Therapeutic, Huyaboiscience, Incyte, Nektar Pharmaceutical, Regeneron, Replimune; Financial Interests, Personal, Funding: BMS, Merck Serono, MSD Novartis, Pierre Fabre; Financial Interests, Institutional, Advisory Board: BMS, Leo Pharma. C. Pages: Financial Interests, Personal, Advisory Board: BMS. C. Lebbe: Financial Interests, Personal, Funding: Roche, BMS, Novartis, Amgen, MSD, Pierre Fabre, Pfizer, Incyte; Financial Interests, Personal, Advisory Role: BMS, MSD, Novartis, Amgen, Roche, Merck Serono, Sanofi, Pierre Fabre; Financial Interests, Personal, Invited Speaker: Roche, BMS, Novartis, Amgen, MSD; Financial Interests, Institutional, Research Funding: Roche, BMS, Novartis, Amgen, MSD; Financial Interests, Personal, Advisory Board: Avantis Medical Systems, InflaRx, Sanofi, BMS, MSD, Pierre Fabre, Novartis, Jazz Pharmaceuticals; Financial Interests, Personal, Other: BMS, MSD, Novartis, Sanofi, Pierre Fabre. All other authors have declared no conflicts of interest.
Resources from the same session
1119P - Stage IIIA melanoma with isolated tumor cells in lymph nodes: Time for reviewing the AJCC v8 classification
Presenter: Teresa Amaral
Session: Poster session 13
1120P - Development and external validation of a clinical prediction model to predict recurrence-free survival and melanoma-specific survival in patients with melanoma after sentinel lymph node biopsy
Presenter: Robert Stassen
Session: Poster session 13
1121P - Interferon-gamma (IFNy) gene signature as a predictive biomarker for response in lactate dehydrogenase (LDH) low advanced melanoma patients
Presenter: Lotte Hoeijmakers
Session: Poster session 13
1122P - Neutrophil/lymphocyte ratio and systemic inflammatory index as prognostic biomarkers in metastatic melanoma patients under immune checkpoint inhibitors: Could any of them be used?
Presenter: Maria Menezes
Session: Poster session 13
1123P - Baseline tumor-infiltrating lymphocytes and response to immune checkpoint inhibition in advanced melanoma
Presenter: Mark Schuiveling
Session: Poster session 13
1124P - IL-6 as prognostic factor in adjuvant or metastatic skin cancer patients treated with immunotherapy: A deep biomarker analysis
Presenter: Domenico Mallardo
Session: Poster session 13
1125P - Identification of a subset of metastatic melanoma patients demonstrating germline determined insensitivity to immunotherapy
Presenter: Benjamin Fairfax
Session: Poster session 13
1126P - REtrospective Study of definitive therapy for head and neck mUcosal MElanoma: The RESUME study
Presenter: Motoo Nomura
Session: Poster session 13
1127P - Efficacy of immune checkpoint inhibitors (ICIs) in advanced mucosal melanoma (MM): A systematic review and meta-analysis
Presenter: James Pham
Session: Poster session 13
1128P - A phase I dose escalation and expansion study of FHD-286, a novel BRG1/BRM (SMARCA4/SMARCA2) inhibitor, for the treatment of metastatic uveal melanoma
Presenter: Sapna Patel
Session: Poster session 13